BIM polymorphism and BIM levels in treatment-naive cancers determine sensitivity to receptor kinase inhibitors, particularly EGFR and mutant B-RAF signaling pathway inhibitors, glucocorticoids, and paclitaxel.48 This evidence concerns the gene EGFR and cancer.